Aromatase inhibitors (AIs) — primarily anastrozole — became routine additions to TRT protocols during the 2010s. The logic seemed sound: TRT increases testosterone, aromatase converts some of that to estradiol, so block aromatase to prevent estrogen-related side effects. The problem is that this logic treats estradiol as the enemy when it's actually an essential hormone for men.
Why AIs Became Standard
Early TRT protocols often used high doses (200mg+ weekly) that produced significant estradiol elevation and genuine estrogenic side effects. Anastrozole controlled these symptoms effectively. The practice then propagated downward — even modest doses with modest estradiol levels got prophylactic AI prescriptions because "that's just what you do on TRT."
The Evidence Against Routine AI Use
Estradiol in men serves critical functions: bone density maintenance (estradiol, not testosterone, is the primary bone-protective hormone in men), cardiovascular endothelial function, joint health, libido support, and neuroprotection. Crushing estradiol with aggressive AI dosing consistently produces joint pain, decreased libido, mood flattening, accelerated bone loss, and potentially increased cardiovascular risk.
The Endocrine Society does not recommend routine AI use on TRT. Their guidelines suggest addressing estradiol concerns through dose adjustment and injection frequency changes first — AI only when symptomatic hyperestrogenism persists despite protocol optimization.
When AIs Are Genuinely Indicated
Appropriate AI Use
- Documented gynecomastia development (breast tissue growth, not just nipple sensitivity) despite optimized TRT dose and frequency
- Symptomatic estradiol elevation (significant water retention, mood disturbance) confirmed by labs AND unresponsive to dose/frequency adjustment
- Always at the lowest effective dose (typically 0.25mg anastrozole twice weekly, not the common 1mg doses)
- With follow-up estradiol monitoring to prevent overcorrection below 15–20 pg/mL
The Bottom Line
Less AI, Better Outcomes
Modern TRT management treats estradiol elevation through dose adjustment and injection frequency optimization — not routine aromatase inhibitors. AIs are reserved for documented, symptomatic hyperestrogenism that doesn't respond to protocol changes. If your TRT provider prescribes anastrozole from day one without baseline estradiol levels, question the approach.